1. Manimekalai P, Sabarinath C, Sowndharya M, Yazhini N, Nivetha M, Thendral J, et al. Review of gouty arthritis: A new perception for the treatment of old diseases. International Journal Of Pharmaceutical Sciences And Research. 2023;14(9):4404-18. doi: 10.13040/IJPSR.0975-8232.
2. López-Reyes A, Medina-Luna D, Santamaría-Olmedo M, Martínez-Flores K, Zamudio-Cuevas Y, Fernández-Torres J, Martínez-Nava GA, Olivos-Meza A, Camacho-Rea C, Fernández-Moreno M, Blanco FJ, Pineda C. Soluble inflammatory mediators of synoviocytes stimulated by monosodium urate crystals induce the production of oxidative stress, pain, and inflammation mediators in chondrocytes : Secretome of synoviocytes induces chondrocyte damage. Clin Rheumatol. 2021 Aug;40(8):3265-3271. doi: 10.1007/s10067-021-05676-w.
3. Zhang Y, Chen S, Yuan M, Xu Y, Xu HJN. Gout and diet: a comprehensive review of mechanisms and management. 2022;14(17):3525.
doi:10.3390/nu14173525
4. Galozzi P, Bindoli S, Doria A, Oliviero F, Sfriso PJJocm. Autoinflammatory features in gouty arthritis. 2021;10(9):1880.
doi:10.3390/jcm10091880
5. Abhishek A, Cipolletta EJCM. Gout on the acute medical take. 2025;25(4):100331.
doi:10.1016/j.clinme.2025.100331
6. Yang S, Zhang B, Tan W, Qi L, Ma X, Wang XJFiG. A novel purine and uric metabolism signature predicting the prognosis of hepatocellular carcinoma. 2022;13:942267.
doi:10.3389/fgene.2022.942267
7. Mileti LN, Baleja JDJM. The role of purine metabolism and uric acid in postnatal neurologic development. 2025;30(4):839.
doi:10.3390/molecules30040839
8. Galozzi P, Bindoli S, Luisetto R, Sfriso P, Ramonda R, Scanu A, et al. Regulation of crystal induced inflammation: current understandings and clinical implications. 2021;17(7):773-87.
doi:10.1080/1744666X.2021.1937129
9. Timsans J, Palomäki A, Kauppi MJJocm. Gout and hyperuricemia: a narrative review of their comorbidities and clinical implications. 2024;13(24):7616.
doi:10.3390/jcm13247616
10. Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. 2024;25(1):1047.
doi:10.1186/s12891-024-08180-9
11. Kaplan GG, Windsor JWJNrG, hepatology. The four epidemiological stages in the global evolution of inflammatory bowel disease. 2021;18(1):56-66.
doi:10.1038/s41575-020-00360-x
12. Chen F, Su X, Yang F, Yu J, Bai C, Zhang MJCR. The global burden and epidemiological trends of gout, particularly cases attributable to high Body Mass Index (BMI) in adolescents and young adults (aged 15-39 years): a secondary analysis from global burden of disease study 2021. 2025:1-14.
doi:10.1007/s10067-025-07494-w
13. Yang F, Chen R, Xiong J, Wang W, Yu P, Wang H. The disease burden of gout in Asian countries and regions from 1990 to 2021, risk factors and forecast analysis: A systematic study of Asian disease burden in 2021. PloS one. 2025;20(7):e0328543.
doi:10.1371/journal.pone.0328543
14. Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, et al. Global epidemiology of rheumatoid arthritis. Nature reviews Rheumatology. 2022;18(10):591-602.
doi:10.1038/s41584-022-00827-y
15. Liu K, Ye D, Lin H, Sun Y, Shen P, Wang J, et al. Incidence and prevalence of gout in Eastern China from 2011 to 2021: a retrospective population-based study. Annals of medicine. 2025;57(1):2561230.
doi:10.1080/07853890.2025.2561230
16. Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC musculoskeletal disorders. 2024;25(1):1047.
doi:10.1186/s12891-024-08180-9
17. Li M, Nie Q, Xia Q, Jiang Z. Assessing cross-national inequalities and predictive trends in gout burden: a global perspective (1990-2021). Frontiers in medicine. 2025;12:1527716. doi:10.3389/fmed.2025.1527716
18. GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024 Aug;6(8):e507-e517. doi: 10.1016/S2665-9913(24)00117-6. Epub 2024 Jul 9. Erratum in: Lancet Rheumatol. 2024 Nov;6(11):e749. doi: 10.1016/S2665-9913(24)00303-5.
19. Heidarian P, Jalali A, Shirzadi A, Jalali R, Ezzati E. Global prevalence of metabolic syndrome in patients with gout: A systematic review and meta-analysis. Nutrition and health. 2025;31(3):879-89.
doi:10.1177/02601060251323013
20. Amiri F, Kolahi AA, Nejadghaderi SA, Noori M, Khabbazi A, Sullman MJM, et al. The Burden of Gout and Its Attributable Risk Factors in the Middle East and North Africa Region, 1990 to 2019. The Journal of rheumatology. 2023;50(1):107-16.
doi:10.3899/jrheum.220425
21. Bazrafshan E, Mostafapoor FK. Survey of medical waste characterization and management in Iran: a case study of Sistan and Baluchestan Province. Waste management & research : the journal of the International Solid Wastes and Public Cleansing Association, ISWA. 2011;29(4):442-50.doi:10.1177/0734242X10374901
22. Jordan S, Maurer B, Toniolo M, Michel B, Distler OJR. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. 2015;54(8):1454-8.
doi:10.1093/rheumatology/keu530
23. Lorenzin M, Ughi N, Ariani A, Raffeiner B, Ceccarelli F, Lucchetti R, et al. Impact of disease duration and gender on the sensitivity and specificity of 2015 ACR/EULAR classification criteria for gout. Cross-sectional results from an Italian multicentric study on the management of crystal-induced arthritis (ATTACk). Clinical and experimental rheumatology. 2022;40(7):1368-77.
doi:10.55563/clinexprheumatol/4rrgyt
24. Cross M, Ong KL, Culbreth GT, Steinmetz JD, Cousin E, Lenox H, et al. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. 2024;6(8):e507-e17.
doi:10.2139/ssrn.4478194
25. Dehlin M, Jacobsson L, Roddy EJNRR. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. 2020;16(7):380-90.
doi:10.1038/s41584-020-0441-1
26. Davatchi F, Sandoughi M, Moghimi N, Jamshidi AR, Tehrani Banihashemi A, Zakeri Z, et al. Epidemiology of rheumatic diseases in Iran from analysis of four COPCORD studies. 2016;19(11):1056-62.
doi:10.1111/1756-185X.12809
27. Amiri F, Kolahi A-A, Nejadghaderi SA, Noori M, Khabbazi A, Sullman MJ, et al. The burden of gout and its attributable risk factors in the Middle East and North Africa region, 1990 to 2019. 2023;50(1):107-16.
doi:10.3899/jrheum.220425
28. McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis and rheumatism. 2012;64(1):121-9.
doi:10.1002/art.33315
29. McAdams-DeMarco MA, Maynard JW, Baer AN, Kao LW, Kottgen A, Coresh J. A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study. Annals of the rheumatic diseases. 2013;72(5):701-6.
doi:10.1136/annrheumdis-2011-201186
30. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology. 2020;16(7):380-90.
doi:10.1038/s41584-020-0441-1
31. Bruderer S, Bodmer M, Jick SS, Meier CRJA, rheumatology. Use of diuretics and risk of incident gout: a population‐based case-control study. 2014;66(1):185-96.
doi:10.1002/art.38203
32. Kannuthurai V, Gaffo AJK. Management of patients with gout and kidney disease: a review of available therapies and common missteps. 2023;4(9):e1332-e40.
doi:10.34067/KID.0000000000000221
33. Abhishek AJD, Aging. Managing gout flares in the elderly: practical considerations. 2017;34(12):873-80.
doi:10.1007/s40266-017-0512-4
34. Foody J, Turpin RS, Tidwell BA, Lawrence D, Schulman KLJAh, benefits d. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. 2017;10(8):393.
35. Mouradjian MT, Plazak ME, Gale SE, Noel ZR, Watson K, Devabhakthuni SJAJoCD. Pharmacologic management of gout in patients with cardiovascular disease and heart failure. 2020;20(5):431-45.
doi:10.1007/s40256-020-00400-6
36. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis & rheumatology (Hoboken, NJ). 2014;66(1):185-96.
doi:10.1002/art.38203
